Rajender Reddy
Overview
Explore the profile of Rajender Reddy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Premkumar M, Kajal K, Gupta P, Reddy R, Reddy K
Semin Liver Dis
. 2025 Jan;
PMID: 39809452
Critically ill patients with cirrhosis and liver failure do not uncommonly have hypotension due to multifactorial reasons, which include a hyperdynamic state with increased cardiac index (CI), low systemic vascular...
2.
Shukla A, Rockey D, Kamath P, Kleiner D, Singh A, Vaidya A, et al.
Hepatol Int
. 2024 Nov;
18(6):1684-1711.
PMID: 39546143
Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information,...
3.
Potluri V, Naqvi F, Goldberg D, Shah M, Loupy A, Abt P, et al.
Kidney Int Rep
. 2023 Jul;
8(7):1460-1463.
PMID: 37441470
No abstract available.
4.
Nagral A, Rudra O, Menezes S, Menon S, Shailajan S, Mallakmir S, et al.
J Clin Exp Hepatol
. 2023 Mar;
13(2):360-371.
PMID: 36950495
Background: (TC) is being increasingly consumed in India for its health and suggested immune-enhancing benefits in preventing and countering COVID-19. We previously published our experience of hepatotoxicity with self-medication of...
5.
Fontana R, Bjornsson E, Reddy R, Andrade R
Clin Gastroenterol Hepatol
. 2023 Mar;
21(8):2088-2099.
PMID: 36868489
Idiosyncratic drug-induced liver injury (DILI) is an infrequent but important cause of liver disease. Newly identified causes of DILI include the COVID vaccines, turmeric, green tea extract, and immune checkpoint...
6.
Eaton J, Vuppalanchi R, Reddy R, Sathapathy S, Ali B, Kamath P
Hepatology
. 2019 Nov;
71(4):1511-1514.
PMID: 31680292
No abstract available.
7.
Bwa A, Nangia G, Win S, Maung S, Han K, Htar S, et al.
J Clin Exp Hepatol
. 2019 Jul;
9(3):283-293.
PMID: 31360020
Background: In resource-constrained areas, generic direct-acting antivirals (DAAs) have considerably reduced the cost of hepatitis C virus (HCV) therapy while there remain significant costs related to the baseline and follow-up...
8.
Younossi Z, Stepanova M, Reddy R, Manns M, Bourliere M, Gordon S, et al.
Liver Int
. 2018 Jun;
39(1):54-59.
PMID: 29893462
Background: Clearance of chronic HCV infection improves quality of life and other patient-reported outcomes (PROs). Lack of placebo-controlled data led to concerns about the extent of contribution of viral eradication...
9.
Davis B, Tillman H, Chung R, Stravitz R, Reddy R, Fontana R, et al.
Liver Int
. 2017 Jan;
37(4):509-513.
PMID: 28128878
Background & Aims: In the United States, nearly 1000 annual cases of heat stroke are reported but the frequency and outcome of severe liver injury in such patients is not...
10.
OLeary J, Fontana R, Brown K, Burton Jr J, Firpi-Morell R, Muir A, et al.
Transpl Int
. 2016 Nov;
30(2):196-208.
PMID: 27896858
This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 postorthotopic liver transplant evaluated once-daily simeprevir 150 mg + sofosbuvir 400 mg, with and...